PATENT CLAIM ANALYSIS

Application Number: 15884221
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["435", "006100"]

Abstract:
A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising obtaining a biological sample from the patient having the hematological cancer; determining the expression level of one, two, three, four, five, or more genes; and comparing the expression level of the one, two, three, four, five, or more genes in the biological sample with a reference expression level of the same genes, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Claim (Index 70):
A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising:\n (a) obtaining a first tumor sample from a first patient having the hematological cancer, (b) measuring the proportion of B cells and/or T cells in the first tumor sample from a first patient, and (c) comparing the proportion of B cells and/or T cells in the first tumor sample from a first patient with the proportion of B cells or T cells in a second tumor sample from a second patient having the same type of hematological cancer, wherein the second patient's hematological cancer is clinically insensitive to treatment with an immunomodulatory therapy, and wherein a different proportion of B cells and/or T cells in the first tumor sample is measured relative the proportion of B cells and/or T cells in the second tumor sample indicates that the hematological cancer in the first patient will be clinically sensitive to treatment with the immunomodulatory therapy, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 2.15
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15273205', '13459005', '15150227', '14381004', '13417088']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5663982074175309
- 35 USC 102 Novelty (BERT): 0.5763677215104488
- Combined Prediction Score: 0.5673951588268227
- Mean Citation Score: 308.514826
- Max Citation Score: 598.8112
- Similarity Product: 357.40016599283217

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test